Repligen Corporation (RGEN)

RGEN tops Q4 EPS estimates as revenues jump 18% Y/Y, with solid organic growth and stronger margins heading into 2026.

Repligen Corporation (RGEN) Q4 2025 Earnings Call Transcript

Repligen (RGEN) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.44 per share a year ago.

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2025, covering the three- and twelve- month periods ended December 31, 2025. The Company is also providing financial guidance for the full year 2026.

In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profitability) and short-term price momentum-oriented stocks outperformed. Exact Sciences Corporation received a buyout offer in the fourth quarter by Abbott Laboratories (ABT) for a price of $105 in cash.

Repligen (NASDAQ: RGEN - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of $0.44 per share and revenue of $192.2250 million for the quarter. Interested persons can check the company's upcoming Q4 2025 earning summary page for the

Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET

Bessemer Group Inc. trimmed its stake in Repligen Corporation (NASDAQ: RGEN) by 95.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,079 shares of the biotechnology company's stock after selling 238,450 shares during the quarter. Bessemer Group Inc.'s

Conestoga Mid Cap Composite Q4 2025 Leaders And Laggards

Repligen Corporation (RGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. As previously communicated1, Tony Hunt is retiring from his role as Executive Chair and member of the Board of Directors effective this March 13th. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027.

Delta Investment Management LLC purchased a new position in Repligen Corporation (NASDAQ: RGEN) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,717 shares of the biotechnology company's stock, valued at approximately $6,779,000. Repligen makes up about 1.2% of

Assenagon Asset Management S.A. purchased a new position in Repligen Corporation (NASDAQ: RGEN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 40,569 shares of the biotechnology company's stock, valued at approximately $5,423,000. Assenagon Asset Management S.A. owned 0.07% of Repligen at the

WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan 2026 Healthcare Conference, being held January 12 – 15 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 13 at 2:15 p.m. PT.

WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new high-performance chromatography resins: AVIPure® HiPer™ AAV9 and AVIPure® HiPer™ AAV8 affinity resins, along with HiPer™ QA anion exchange resin, expanding the company's growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. Built on the Tantti™ DuloCore™ base bead technology, the new convective HiPer resins deliver the differentiated performance required for new modalities, including viral vectors. These solutions are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, ultimately enabling faster, more reliable paths to market. As momentum continues across new modalities, Repligen remains focused on providing customers with the cutting-edge tools they need. These new resins extend the company's leadership in process productivity and strengthen its portfolio ahead of broader chromatography resin launches anticipated in 2026. “These new resins further expand our growing proteins portfolio with purpose-built, next-generation tools that leverage both our AVIPure® affinity ligands and HiPer™ bead technologies,” said Umay Saplakoğlu, Vice President, Proteins and Incubator at Repligen. “Gene therapy manufacturers need scalable, high-performance solutions. Our latest AAV8 and AAV9 resins, along with our HiPer QA anion-exchange resin, are designed to deliver significantly faster processing and robust performance across today's increasingly complex biotherapeutic workflows.” About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn. This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law. Repligen Contact: Jacob JohnsonVP, Investor Relations781-419-0204investors@repligen.com

AWM Investment Company Inc. lowered its position in shares of Repligen Corporation (NASDAQ: RGEN) by 21.1% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 45,000 shares of the biotechnology company's stock after selling 12,000 shares during the quarter. AWM Investment Company Inc. owned about